Abstract
Gene delivery/expression vectors have been used as fundamental technologies in gene therapy since the 1980s. These technologies are also being applied in regenerative medicine as tools to reprogram cell genomes to a pluripotent state and to other cell lineages. Rapid progress in these new research areas and expectations for their translation into clinical applications have facilitated the development of more sophisticated gene delivery/expression technologies. Since its isolation in 1953 in Japan, Sendai virus (SeV) has been widely used as a research tool in cell biology and in industry, but the application of SeV as a recombinant viral vector has been investigated only recently. Recombinant SeV vectors have various unique characteristics, such as low pathogenicity, powerful capacity for gene expression and a wide host range. In addition, the cytoplasmic gene expression mediated by this vector is advantageous for applications, in that chromosomal integration of exogenous genes can be undesirable. In this review, we introduce a brief historical background on the development of recombinant SeV vectors and describe their current applications in gene therapy. We also describe the application of SeV vectors in advanced nuclear reprogramming and introduce a defective and persistent SeV vector (SeVdp) optimized for such reprogramming.
Keywords: Sendai virus, gene therapy, nuclear reprogramming, induced pluripotent stem cells (iPSCs), regenerative medicine, viral vectors, gene delivery vectors, DNA–carrier
Current Gene Therapy
Title:Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Volume: 12 Issue: 5
Author(s): Mahito Nakanishi and Makoto Otsu
Affiliation:
Keywords: Sendai virus, gene therapy, nuclear reprogramming, induced pluripotent stem cells (iPSCs), regenerative medicine, viral vectors, gene delivery vectors, DNA–carrier
Abstract: Gene delivery/expression vectors have been used as fundamental technologies in gene therapy since the 1980s. These technologies are also being applied in regenerative medicine as tools to reprogram cell genomes to a pluripotent state and to other cell lineages. Rapid progress in these new research areas and expectations for their translation into clinical applications have facilitated the development of more sophisticated gene delivery/expression technologies. Since its isolation in 1953 in Japan, Sendai virus (SeV) has been widely used as a research tool in cell biology and in industry, but the application of SeV as a recombinant viral vector has been investigated only recently. Recombinant SeV vectors have various unique characteristics, such as low pathogenicity, powerful capacity for gene expression and a wide host range. In addition, the cytoplasmic gene expression mediated by this vector is advantageous for applications, in that chromosomal integration of exogenous genes can be undesirable. In this review, we introduce a brief historical background on the development of recombinant SeV vectors and describe their current applications in gene therapy. We also describe the application of SeV vectors in advanced nuclear reprogramming and introduce a defective and persistent SeV vector (SeVdp) optimized for such reprogramming.
Export Options
About this article
Cite this article as:
Nakanishi Mahito and Otsu Makoto, Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine, Current Gene Therapy 2012; 12 (5) . https://dx.doi.org/10.2174/156652312802762518
DOI https://dx.doi.org/10.2174/156652312802762518 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
γ-Tocotrienol Induces Apoptosis in Human T Cell Lymphoma through Activation of Both Intrinsic and Extrinsic Pathways
Current Pharmaceutical Design Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
Reviews on Recent Clinical Trials Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design Development of Vasculature Targeting Strategies for the Treatment of Chronic Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Potential of Taming MicroRNA on Driver Seat to Control Mitochondrial Horses in Breast Carcinoma
MicroRNA Patent Selections
Recent Patents on Biomarkers HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets The Medical Potential of Antimicrobial Peptides from Insects
Current Topics in Medicinal Chemistry Clinical Applications of Cardiovascular Magnetic Resonance
Current Pharmaceutical Design Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology Lung Cancer May Increase Serum Procalcitonin Level
Infectious Disorders - Drug Targets Modulating Fatty Acid Metabolism and the AMP-Activated Protein Kinase Pathway as a Target for Obesity Therapy
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Base Excision Repair, the Redox Environment and Therapeutic Implications
Current Molecular Pharmacology Altered Hyaluronan Biosynthesis and Cancer Progression: an Immunological Perspective
Mini-Reviews in Medicinal Chemistry Toxicological Aspects of Carbon Nanotubes, Fullerenes and Graphenes
Current Pharmaceutical Design